ClinicalTrials.gg
RecruitingNCT04110041Updated Apr 12, 2024

Effects of Aerobic Exercise Intensity on Clinical & Neural Outcomes in Depressed Youth

An interventional study of Aerobic Exercise in Depression, sponsored by The Royal's Institute of Mental Health Research. Recruiting at 1 site in Canada. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by The Royal's Institute of Mental Health Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2018, registered Sep 2019).
  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
16 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 533 studies in Depression with a site in Canada — 107 open to participants now, 124 under way, 7 of them phase 3. Depression · Canada.

Planned enrollment
341st of 488
40 · median 77
Started
2018
with 34 others
No phase
334 of 533
78 open now
Primary completion
2025-09
later than 23 of 123 live
Registered
291st of 533
by date

Among the 533 studies in Depression with a site in Canada, this one is the 341st largest by planned enrollment of the 488 interventional ones that give a count, is one of 35 that started in 2018, is one of 334 with no phase, reaches primary completion later than 23 of the 123 other live ones, and was the 291st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

107 of the 533 studies in Depression with a site in Canada are open now. Recruiting first, the newest first:

102 more — sign in →

All 107 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 16 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 533 studies in Depression with a site in Canada, or all of them as a file.
02

Study summary

This study will assess the effects of moderate vs. high intensity aerobic exercise, performed 3 times a week for 12 weeks under supervised conditions, on symptoms of depression, cognitive functioning and brain function in transitional aged youth (TAY: aged 16-24 years).

Read the detailed description

Rationale: Major depressive disorder (MDD) is a debilitating disorder characterized by persistent negative mood and a broad range of cognitive, and functional impairments. MDD is estimated to affect 4.4% of the global population, or over 300 million individuals, representing the single largest contributor to non-fatal health loss worldwide. Current treatment options are associated with sub-optimal rates of remission, with only 30-35% of MDD sufferers attaining remission with antidepressant drug monotherapy. One group for whom treatment selection is a particular challenge is transitional aged youth (TAY), encompassing the late teenage years into the early twenties. Although MDD onset typically occurs during this period - as high as 8.2% in Canadian TAY - the psychiatric community has only recently begun to recognize TAY as a unique psychiatric cohort in need of directed treatment. For example, although the use selective serotonin reuptake inhibitors (SSRIs) is the first-line treatment for MDD in adults, their utility in TAY is hampered by the possibility of increased suicidal ideation within this cohort. The need for alternative and tailored treatment options for TAY with MDD is therefore of paramount importance. Aerobic exercise (AE) has recently been recognized as one such intervention, with some reports showing outcomes comparable to pharmacological and psychotherapeutic approaches in adult populations. Few studies however, have investigated to what extent these findings extend to TAY. Further, there is little consensus as to which intensity level, or "dose", of AE offers the most benefit, which neural features underlie the putative benefits of AE in depressed TAY, and the impact on both psychosocial and cognitive processes.

Objectives: The primary objectives of this study are: 1) to determine the effects of moderate vs. high intensity AE on clinically-rated and subjective symptoms of MDD in TAY; and 2) to examine the psychosocial, cognitive, and neuromodulatory effects of these interventions.

Methods: This two-arm, randomized trial will recruit 40 TAY (16-24 yrs) with MDD/persistent depressive disorder (PDD) into one of two AE intensity groups: medium or high. Intensity is defined as a percentage of heart rate reserve (HRR) achieved during exercise, as outlined in the American College of Sports Medicine (ACSM) guidelines (moderate: 50-55% of HRR; N=20; high: 80-85% HRR; N=20). All participants will undergo supervised and guided AE intervention sessions (\~30min), three times per week, for twelve consecutive weeks. Pertinent clinical and psychosocial scores, as well as cardiac function (as assessed by maximal oxygen consumption [VO2max]), will be recorded pre-intervention (Week 0), mid-intervention (Week 6), and post-intervention (Week 12). Additionally, participants will undergo electroencephalographic (EEG) and functional magnetic resonance neuroimaging (fMRI) before and after the completion of AE intervention. Specifically, neural dynamics will be recorded at rest and during cognitive tasks engaging working memory (N-Back task) and response inhibition (Flanker task) - cognitive abilities, which have been shown to be impaired in MDD in TAY. Both clinical/psychosocial and neuroimaging outcomes will be compared using time as the within-group, and intervention type as between-group factors.

Hypotheses: The investigators expect a significant reduction in depression symptoms post (vs. pre) intervention and, based on preliminary evidence in adults, a greater reduction may emerge in those participating in the high (vs. moderate) intensity AE. Further, the investigators expect changes in fMRI profiles from pre- to post-intervention (showing normalization of brain activity and connectivity profiles); the same is true of EEG/event-related potential (ERP) features. They also expect a positive relation between VO2max and brain-based changes.

Significance: Findings from this project will help guide future large-scale investigations of AE as a potential treatment for TAY by clarifying the relation between changes to physical indices, depressive symptoms and neural profiles. Importantly, identifying the brain features modulated by AE will broaden our understanding of the neurobiological markers underlying depressive states, allowing for targeted therapeutic approaches and better outcomes for TAY suffering from MDD.

03

Conditions studied

  • Depression

Browse trials for

Keywords

  • Transitional-aged youth
  • Exercise therapy
  • Neurocognition
  • fMRI
  • EEG
04

Who can participate

Ages eligible
16 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently experiencing depression (MDD or PDD);
  • Free of pharmacotherapy (ie. antidepressant medication) for >5 weeks;
  • Not currently engaging in regular moderate or vigorous intensity exercise;
  • Able to read/understand English;
  • [BMI] \< 40;
  • Medically cleared to engage in aerobic exercise.

Exclusion criteria

Exclusion Criteria:

  • Currently engaged in another exercise trial;
  • Another Axis I/II disorder, apart from co-morbid anxiety disorder(s);
  • Current or lifetime history of serious medical or neurological conditions;
  • Currently taking psychoactive drugs (occasional use of anti-anxiety medication permitted);
  • Regular user of nicotine products;
  • Unstable medical conditions, especially those that prevent exercise;
  • Exhibiting significant suicide risk;
  • MRI ;
  • Currently pregnant or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Moderate Intensity

    Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).

    Behavioral: Aerobic Exercise

  • Experimental
    High Intensity

    Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).

    Behavioral: Aerobic Exercise

Interventions

  • BehavioralAerobic Exercise

    Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Changes in clinician-rated depression-related symptoms

    Changes in depressive symptoms as measured by the Hamilton Depression Rating Scale (HDRS) \& Montgomery-Asberg Depression Rating Scale (MADRS).

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)

  2. Changes in self-reported depression-related symptoms

    Changes in depressive symptoms as measured by the Beck Depression Inventory (BDI; self-reported)

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks), 3-month follow-up, 6-month follow-up

  3. Feasibility of moderate & high intensity aerobic exercise as a treatment regimen.

    Operationalized as: a) recruitment and randomization - the number of individuals who are successfully screened into the study, and the number of individuals randomized to each treatment following successful screening, respectively, over a 24 month period; and b) retention - the extent to which participants remain enrolled in the study, ie the number of participants who complete follow-up testing.

    Time frame: Every 24 months from recruitment initiation until study completion

  4. Adherence to moderate & high intensity exercise regimens as prescribed

    The number of exercise session attended by each participant (out of the total 36 sessions prescribed).

    Time frame: Assessed per participant, through study completion

  5. Compliance to moderate & high intensity exercise regimens as prescribed

    The percentage of time, per session, that a participant spends within his/her prescribed heart rate zone.

    Time frame: Assessed per participant, through study completion

Secondary outcomes

  1. Changes in electrocortical-indexed brain activity profiles

    Assessed via EEG during computerized tasks of attention/inhibition and working memory.

    Time frame: Baseline & Post-Intervention (12 weeks)

  2. Changes to neuroimaging-indexed brain activity profiles

    Assessed via fMRI during computerized tasks of attention/inhibition and working memory.

    Time frame: Baseline & Post-Intervention (12 weeks)

  3. Changes to self-esteem

    Assessed with the Rosenberg Self-Esteem Scale, a 10-item self-report questionnaire.

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)

  4. Changes in self-mastery

    Assessed with Perlin/Schooler's Mastery Scale a 7-item self-report questionnaire.

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)

  5. Changes in daily functioning

    Assessed via the Columbia Impairment Scale, a 13-item self-report questionnaire.

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)

  6. Changes in cognitive function

    Assessed via the NIH Cognitive Toolbox; a cognitive battery consisting of 7 distinct computerized tasks assessing multiple cognitive constructs. Performance on each task is combined to produce a composite score.

    Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Sep 2025, 84 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 84 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Oct 1, 2019
StartActual
Aug 7, 2018
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04110041
Lead sponsor
The Royal's Institute of Mental Health Research
Responsible party
Dr. Natalia Jaworska (Director, Clinical Electrophysiology Laboratory, The Royal's Institute of Mental Health Research) — Principal investigator
First posted
Oct 1, 2019
Start date
Aug 7, 2018
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Apr 12, 2024

Study contacts

Natalia Jaworska, PhD
Contact
Natalia.Jaworska@theroyal.ca
613-722-6521 ext. 6843

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion